D&A at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's D&A?
- Halozyme Therapeutics (HALO) reported D&A of $4.22M in Q1 2026.
- How has Halozyme Therapeutics's D&A changed year-over-year?
- Halozyme Therapeutics's D&A increased by 57.1% year-over-year, from $2.69M to $4.22M.
- What does D&A mean?
- The non-cash expense representing the wear and tear or expiration of assets over time.
- How do you interpret D&A?
- Higher levels indicate significant capital intensity or recent large acquisitions of intangible assets, while lower levels suggest an asset-light business model.
- How does D&A compare across companies?
- Common in capital-intensive industries; biotech firms often have high amortization due to acquired patents and drug licenses.